Results 181 to 190 of about 22,306,541 (256)
Some of the next articles are maybe not open access.
European Journal of Ophthalmology, 2010
Purpose Mitomycin C after photorefractive keratectomy (PRK) is used to reduce the development of haze and regression in higher intended corrections. The aim of this study was to investigate the safety, stability, and efficacy of EpiLASIK with mitomycin C. Methods Fifty eyes of 29 patients underwent EpiLASIK with the Gebauer EpiLift microkeratome.
Christoph, Winkler von Mohrenfels +3 more
openaire +2 more sources
Purpose Mitomycin C after photorefractive keratectomy (PRK) is used to reduce the development of haze and regression in higher intended corrections. The aim of this study was to investigate the safety, stability, and efficacy of EpiLASIK with mitomycin C. Methods Fifty eyes of 29 patients underwent EpiLASIK with the Gebauer EpiLift microkeratome.
Christoph, Winkler von Mohrenfels +3 more
openaire +2 more sources
Cancer Treatment Reviews, 1976
Summary Preclinical 1. Mitomycin C is an alkylating agent requiring reduction of the quinone to be active. 2. The aziridine ring is essential for the antitumor activity of mitomycin C. 3. The degree of DNA cross-linking and tumor inhibition is proportional to the guanine and cytosine content of the DNA. 4.
S T, Crooke, W T, Bradner
openaire +2 more sources
Summary Preclinical 1. Mitomycin C is an alkylating agent requiring reduction of the quinone to be active. 2. The aziridine ring is essential for the antitumor activity of mitomycin C. 3. The degree of DNA cross-linking and tumor inhibition is proportional to the guanine and cytosine content of the DNA. 4.
S T, Crooke, W T, Bradner
openaire +2 more sources
Mitomycin C (z.B. Mitomycin C „Kyowa“)
2006aufgrund zahlreicher Berichte uber Nekrosen wird Mitomycin C als gewebsnekrotisierend ...
openaire +1 more source
Mitomycin C extravasation ulcers
Journal of Surgical Oncology, 1985AbstractIn a four‐year period, eight patients with mitomycin C extravasation ulcers were encountered. Mitomycin C extravasation produces a painful indolent ulcer that does not have any tendency to heal. If extravasation of the drug is recognized, infusion should be stopped immediately, and the site of infusion should be changed.
A K, Khanna +3 more
openaire +2 more sources
Bacteriocidal action of mitomycin C
Biochimica et Biophysica Acta, 1960Abstract The bacteriocidal action of Mitomycin C has been investigated with respect to its biochemical, genetic and morphological correlates. All findings are consistent with the observation that cells treated with Mitomycin lose DNA, but not RNA or protein, to the surrounding medium.
E, REICH, A J, SHATKIN, E L, TATUM
openaire +3 more sources
Mitomycin-C in Congenital Glaucoma
Ophthalmic Surgery, Lasers and Imaging Retina, 1997* BACKGROUND AND OBJECTIVE: To evaluate the adjunctive use of mitomycin-C (MMC) during trabeculotomy and trabeculectomy for eyes with highrisk congenital glaucoma. * PATIENTS AND METHODS: A prospective, randomized, double-blind study was performed to compare the effect of a single, 4-minute intraoperative exposure to 0.2 mg/ml (group 1) or 0 ...
H C, Agarwal +4 more
openaire +2 more sources
Dacryocystorhinostomy with Intraoperative Mitomycin C
Ophthalmology, 1997To observe the effect of intraoperative mitomycin C on the size of the osteotomy site after dacryocystorhinostomy.:A total of 15 eyes of 14 patients diagnosed with primary acquired nasolacrimal duct obstruction were assigned randomly to either a mitomycin C group or a control group.
S C, Kao +4 more
openaire +2 more sources
American Journal of Clinical Oncology, 1984
The clinical spectrum and the pathological findings of renal toxicity in four patients treated with mitomycin-C are described. Our experience and evidence in the literature indicates that the renal impairment appears to be total-dose-related, with most patients developing renal symptoms after receiving at least 60 mg of mitomycin-C.
T S, Ravikumar +3 more
openaire +2 more sources
The clinical spectrum and the pathological findings of renal toxicity in four patients treated with mitomycin-C are described. Our experience and evidence in the literature indicates that the renal impairment appears to be total-dose-related, with most patients developing renal symptoms after receiving at least 60 mg of mitomycin-C.
T S, Ravikumar +3 more
openaire +2 more sources
Cancer chemotherapy and biological response modifiers, 1994
In conclusion, recent work has highlighted the fact that NSCLCs have elevated levels of NQO1 activity and that such an increase represents an excellent target for therapeutic exploitation. The 5-year survival rate seen with lung cancer is dismal and there is a high number of cancer deaths associated with this disease each year.
N W, Gibson, D, Ross
openaire +1 more source
In conclusion, recent work has highlighted the fact that NSCLCs have elevated levels of NQO1 activity and that such an increase represents an excellent target for therapeutic exploitation. The 5-year survival rate seen with lung cancer is dismal and there is a high number of cancer deaths associated with this disease each year.
N W, Gibson, D, Ross
openaire +1 more source
Mitomycin C in Photorefractive Keratectomy
Journal of Refractive Surgery, 2009Purpose: To evaluate the outcome of primary or retreatment photorefractive keratectomy (PRK) or photo-therapeutic keratectomy (PTK) with mitomycin C (MMC) 0.02% applied prophylactically intraoperatively for the prevention of haze and regression in cases of significant haze and regression after primary PRK, due to previous ...
Ashraf, Shalaby +2 more
openaire +2 more sources